Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ESLA

Estrella Immunopharma Inc

Oct 04 • 04:00PM ET

1.15

Dollar change +0.04
Percentage change 3.60	%

Healthcare • Biotechnology • USA • NASD

Held by: IWC VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.93	Insider Own	75.60%	Shs Outstand	36.61M	Perf Week	-3.36%
Market Cap	41.62M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	8.83M	Perf Month	8.49%
Income	-7.31M	PEG	-	EPS next Q	-	Inst Own	0.34%	Short Float	0.11%	Perf Quarter	-7.26%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	4.21%	Short Ratio	0.05	Perf Half Y	0.00%
Book/sh	0.12	P/B	9.85	EPS next Y	-	ROA	-	Short Interest	0.01M	Perf Year	-61.02%
Cash/sh	0.12	P/C	9.98	EPS next 5Y	-	ROE	-	52W Range	0.81 - 3.50	Perf YTD	3.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-171.09%	52W High	-67.14%	Beta	0.18
Dividend TTM	-	Quick Ratio	24.65	Sales past 5Y	-	Gross Margin	-	52W Low	41.98%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	24.65	EPS Y/Y TTM	-951.34%	Oper. Margin	0.00%	RSI (14)	51.48	Volatility	20.64% 20.80%
Employees	-	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-230.98%	Payout	-	Rel Volume	0.19	Prev Close	1.11
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	196.36K	Price	1.15
SMA20	9.83%	SMA50	-9.26%	SMA200	0.19%	Trades		Volume	38,168	Change	3.60%

Sep-27-24 12:00PM	Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS T-cells (Business Wire) +22.69%
Aug-14-24 12:00PM	Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member (Business Wire)
Aug-02-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -18.08%
May-20-24 10:52AM	ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024 (InvestorPlace)
Sep-29-23 10:34AM	TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination (PR Newswire) -6.22%
05:00PM	Loading…
Sep-18-23 05:00PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire) +34.29% -17.25%
Aug-18-23 04:30PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire)
Jul-18-23 04:30PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire)
Jul-12-23 07:00AM	TradeUP Acquisition Corp. Announces Meeting Date for Stockholders to Approve the Business Combination with Estrella Biopharma, Inc. and Liquidation of Investments Held in the Trust Account into Cash (PR Newswire)

Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies with the capacity to address treatment and safety challenges for patients with blood cancers and solid tumors. The company is headquartered in Emeryville, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ESLA

Estrella Immunopharma Inc

Upgrade your FINVIZ experience